Evidence map›Paper›PMID 41997619›Full record

ArticleOpen heart2026

Long-term outcome in adults with a previous Ross operation: a cohort study.

Mostafa Mahmoud, Bengt Johansson, Daniel Rinnström, Camilla Sandberg, Christina Christersson, Peder Sörensson, Alexandra Trzebiatowska-Krzynska, Zacharias Mandalenakis, Joanna Hlebowicz, Johan Ljungberg

Abstract read
In one paragraph

Article in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mostafa MahmoudDepartment of Diagnostics and Intervention, Umeå University, Umeå, Sweden.
Bengt JohanssonDepartment of Diagnostics and Intervention, Umeå University, Umeå, Sweden bengt.johansson@umu.se.ORCID 0000-0003-0976-6910
Daniel RinnströmDepartment of Diagnostics and Intervention, Umeå University, Umeå, Sweden.
Camilla SandbergDepartment of Community Medicine and Rehabilitation, Umeå University, Umeå, Sweden.ORCID 0000-0002-4043-7130
Christina ChristerssonDepartment of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
Peder SörenssonDepartment of Medicine, Solna, Karolinska Institutet, Stockholm, Stockholm, Sweden.
Alexandra Trzebiatowska-KrzynskaDepartment of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Zacharias MandalenakisDepartment of Institute of Medicine, Gothenburg university Sahlgrenska Akademin, Gothenburg, Sweden.
Joanna HlebowiczDepartment of Cardiology, Skåne University Hospital, Lund, Sweden, Lunds Universitet, Lund, Sweden.ORCID 0000-0002-9515-7240
Johan LjungbergDepartment of Public Health and Clinical Medicine, Umeå Universitet, Umeå, Sweden.ORCID 0000-0002-3002-4877

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn aortic valve disease, several interventions are available. In young people who are still growing, or considering the risks of long-term anticoagulation, the Ross procedure remains an alternative for aortic valve replacement. This procedure entails the transposition of the patient's pulmonary valve to the aortic position, with placement of a homograft in the pulmonary position. However, long-term prognosis remains largely unknown.

methodsThe Swedish national registry of congenital heart disease was searched for adult patients with a history of Ross operation.

results82 patients (mean age 40.4±15.8 years) were identified, with a mean age at the time of the Ross procedure of 23.6±14.7 years. After a mean follow-up of 16.8±5.5 years, 24.4% of patients underwent a first reoperation involving either the neoaortic valve or the pulmonary homograft, at a mean age of 32.0±13.9 years. The cumulative incidence of reoperation was approximately 15% at 10 years and 30% at 20 years post-Ross procedure. Among the 20 reinterventions, 17 (85.0%) involved the pulmonary valve and 8 the neoaortic valve; five patients underwent procedures on both valves. Two patients (2.3%) died during follow-up.Forty-eight patients in the cohort had undergone primary Ross surgery. This subgroup was older at the time of data extraction (mean age 46.7±15.7 years) compared with those who underwent secondary Ross surgery (mean age 31.3±10.7 years), that is, typically following previous interventions. The secondary Ross group demonstrated better left ventricular function, with ejection fraction >50% in 91.7% of cases, compared with 69.8% in the primary group (p=0.041).

conclusionOne in four patients undergoing the Ross procedure requires a reintervention, commonly involving the pulmonary valve. Long-term mortality was low. In selected patients, the Ross procedure remains a viable option; however, late morbidity must be considered. Our findings suggest that secondary Ross surgery is associated with better long-term outcomes, particularly regarding left ventricular function, although the underlying mechanisms remain unclear.

Indexed as

Aortic ValveAortic Valve DiseaseHeart Valve Prosthesis ImplantationPostoperative ComplicationsPulmonary ValveAdolescentAdultFemaleFollow-Up StudiesHumansMaleMiddle AgedRegistriesReoperationRisk FactorsSwedenAortic Valve StenosisEpidemiologyHeart Defects, CongenitalHeart Valve Prosthesis Implantation

Identifiers

PMID41997619
PMCPMC13110713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.